DIT309 for advanced bone and soft tissue sarcomas
Part of Cancer clinical trials.
This trial tests a new cell therapy called DIT309 for people with advanced bone or soft tissue sarcoma that hasn't responded to standard treatments. It aims to see if this therapy is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bone or soft tissue sarcoma that standard treatments have stopped working for.
- You have at least one tumor that can be measured on scans.
- Your tumor tests positive for a specific target protein.
- You are generally healthy enough for daily activities (ECOG score 0-1).
- You have adequate organ function (blood, kidney, liver, and clotting).
- You can undergo a procedure to collect white blood cells (leukapheresis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial tests whether a medicine injected directly into a tumor can shrink or control advanced soft tissue sarcoma. It mainly looks for people whose tumors can be safely injected with a hand exam or ultrasound.
This trial tests a new drug called HS-20093 combined with other treatments for people with advanced bone or soft tissue sarcoma. It aims to find safe and effective combinations for those who haven't responded to standard treatments.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if this combination can help when other treatments have stopped working.
This study tests whether giving radiation, chemotherapy, and immunotherapy together can control high-risk soft tissue sarcoma that is hard to remove or may come back after surgery. It may help by attacking cancer in different ways, including boosting the immune system.
This trial tests a combination of immunotherapy (a treatment that helps your immune system attack cancer) and artificial intelligence (AI) technology as the first treatment for certain types of advanced soft tissue sarcoma. It aims to see if this approach can shrink tumors or stop them from growing better than current options.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.